# Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

> **NCT00841672** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 485 (actual)

## Conditions studied

- Moderate to Severe Hypertension

## Interventions

- **DRUG:** Aliskiren/amlodipine 300/10 mg tablet
- **DRUG:** Amlodipine 10 mg capsule

## Key facts

- **NCT ID:** NCT00841672
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2011-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00841672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00841672, "Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00841672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*